A tight link between dysregulations in mRNA decay mechanisms and cancer hallmarks is now clearly established. Notably, abnormal stabilization of transcripts encoding pro-tumoral cytokines, chemokines or proto-oncogenes occurs during tumor development and progression. My research aims at deciphering the mechanisms involved in such dysregulations and focus on 2 key players in the control of mRNA fate: the Tristetraprolin zinc finger proteins TTP/ZFP36 and Tis11b/ZFP36L1, and microRNAs. I am using an integrative approach combining cellular and molecular biology, preclinical models and translational/clinical studies. The research program runs along 3 complementary axes: 1) the study of the molecular mechanisms through which TTP proteins and microRNAs regulate mRNA decay in normal and cancer cells; 2) the search for alterations in mRNA stability regulators (TTP proteins and microRNAs) in adrenocortical cancer and their evaluation as potential diagnostic/prognostic biomarkers; 3) the development of preclinical anti-cancer therapies targeting mRNA stability regulators in adrenocortical cancer.
A tight link between dysregulations in mRNA decay mechanisms and cancer hallmarks is now clearly established. Notably, abnormal stabilization of transcripts encoding pro-tumoral cytokines, chemokines or proto-oncogenes occurs during tumor development and progression. My research aims at deciphering the mechanisms involved in such dysregulations and focus on 2 key players in the control of mRNA fate: the Tristetraprolin zinc finger proteins TTP/ZFP36 and Tis11b/ZFP36L1, and microRNAs. I am using an integrative approach combining cellular and molecular biology, preclinical models and translational/clinical studies. The research program runs along 3 complementary axes: 1) the study of the molecular mechanisms through which TTP proteins and microRNAs regulate mRNA decay in normal and cancer cells; 2) the search for alterations in mRNA stability regulators (TTP proteins and microRNAs) in adrenocortical cancer and their evaluation as potential diagnostic/prognostic biomarkers; 3) the development of preclinical anti-cancer therapies targeting mRNA stability regulators in adrenocortical cancer.